Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene ® and low dose Proleukin ® in REmission MAINtenance in Acute Myeloid Leukemia
Ceplene Currently Approved in Europe and Israel
REMAIN™ to be a pivotal study for US approval
NEW YORK, Feb. 17, 2017 -- Immune Pharmaceuticals Inc. (Nasdaq: IMNP), will announce on Monday, February 20th, 2017 at the Acute Leukemia XVI symposium in Munich, Germany that it will be launching REMAIN™, an international Overall Survival clinical study with the combination of Ceplene®, the Company's flagship product for Acute Myeloid Leukemia (AML) remission maintenance and relapse prevention, and low dose Proleukin®. Patient recruitment is expected to start in later 2017.
- Category: Biotech
- Published: 17 February 2017
- Written by Editor